PA
EBS icon

Procyon Advisors’s Emergent Biosolutions EBS Stock Holding History

Procyon Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-108
Closed -$9K – 418
2020
Q2 		$9K Buy
108
+12
+13% +$894 ﹤0.01% 672
2020
Q1 		$6K Sell
96
-56
-37% -$3.23K ﹤0.01% 674
2019
Q4 		$8K Buy
+152
New +$8.24K ﹤0.01% 700

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Procyon Advisors's EBS Position: Q3 2020 in Review

Procyon Advisors sold out of Emergent Biosolutions (EBS) in Q3 2020, closing a stake of 108 shares — an estimated $9K sold.

Procyon Advisors first reported a position in EBS in Q4 2019 and held it in 3 quarters. The position peaked at $9K in Q2 2020. 358 funds tracked by Wall St. Rank hold EBS as of Q3 2020.

  • Procyon Advisors reported no remaining Emergent Biosolutions position as of Q3 2020 after selling out during the quarter.
  • Procyon Advisors sold 108 Emergent Biosolutions shares in Q3 2020, an estimated $9K.
  • Procyon Advisors first reported a position in Emergent Biosolutions in Q4 2019 and held it in 3 quarters.
  • Procyon Advisors's Emergent Biosolutions position peaked at $9K in Q2 2020.
  • 358 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2020.

Based on Procyon Advisors's 13F filing for Q3 2020, filed 22 Oct 2020.